| Literature DB >> 35028016 |
Yen Wu1,2,3, Yao-Yu Chung1,3, Yu-Tang Chin1,3, Chi-Yu Lin1,3, Po-Jan Kuo4, Ting-Yi Chen1,2,3, Tzu-Yu Lin1,2,3, Hsien-Chung Chiu4, Haw-Ming Huang1, Jiiang-Huei Jeng5,6, Sheng-Yang Lee1,2,3.
Abstract
BACKGROUND/Entities:
Keywords: 2,3,5,4′-tetrahydroxystilbene-2-O-B-glucoside; Dental pulp stem cells; Expansion
Year: 2021 PMID: 35028016 PMCID: PMC8740205 DOI: 10.1016/j.jds.2021.09.021
Source DB: PubMed Journal: J Dent Sci ISSN: 1991-7902 Impact factor: 2.080
Figure 1Experimental protocol for the culture system of a spinner flask with microcarriers For the 3D culture, human DPSCs were first cultured in a 10 cm dish until they reached 80%–90% confluence. (A) The cells were detached and well mixed with microcarrier beads in a tube. Then, the cell–bead mixture was placed into a spinner flask in DMEM containing 2.5% FBS. After 24 h' starvation, cells were treated with 0.1 and 10 μM THSG in low-glucose DMEM with 2.5% FBS at 30-rpm agitation. The medium was refreshed every day, and cells were collected on days 0, 3, 6, 9, and 12 for further analysis. (B) Optical microscope image of DPSCs attached to cytodex1 microcarriers. Cells were observed on days 0 and 12 under a light microscope (× 100 magnification).
Primers used for qPCR. To examine the proliferation and multi-differentiation effects of 2D and 3D systems on THSG-treated DPSC, the mRNA associated with proliferation (PCNA, Cyclin D1, RRM2, and SIRT1), adipogenesis (LPL and PPAR), neurogenesis (PAX6, DCX, and SOX1), osteogenesis (ALP, RUNX2, and BGLAP), pluripotency (NANOG, POU5F1, SOX2, LIN28, JAK2 and STAT3), oncogenesis (Ras, HER2, SRC, and C-Sis), and apoptosis (p53, BAD, and p21) were measured. All genes expression levels are normalized to 18S reference genes.
| Primer | Forward sequence | Reverse sequence | Accession No. |
|---|---|---|---|
| TCTGAGGGCTTCGACACCTA | TCATTGCCGGCGCATTT TAG | NM_002592.2 | |
| CAAGGCCTGAACCTGAGGAG | GATGACTCTGGAGAGGAAGCG | NC_000011.10 | |
| GGAATCCCTGAAACCCGAGG | TGGCTAAA TCGCTCCACCAAG | NM_001165931. | |
| 1 | |||
| TTGGGTACCGAGATAACCTTCT | TTGCATGTGAGGCTCTATCC | NM_012238.4 | |
| CCGCGCCCGCTATCCT | GGTCAGATGTTAACTGATGTTCCAA | NM_000478.5 | |
| CCGGAATGCCTCTGCTGTTA | AACTCTTGCCTCGTCCACTC | XM_011514961. | |
| 2 | |||
| GGATGACCCCCAAATAGCCC | TTATACCCTCTGGGCTGTGC | NM_199173.5 | |
| AGTAGCAGAGTCCGTGGCTA | ATTCCTGTTACCGTCCAGCC | NM_000237.3 | |
| ACGAGAGTCAGCCTTTAACGAA | CCACGGAGCTGATCCCAAAG | NM_138711.3 | |
| CGTGGGAGAAGTTGGAATCTGAG | GAGAGTTTTCTCCACGGATGTTG | NM_001310158. | |
| 1 | |||
| TGACTCAGCAAACGGAACCT | GCGTAGAGATGGGAGACTGC | NM_178153.3 | |
| AATACTGGAGACGAACGCCG | AACCCAAGTCTGGTGTCAGC | NM_005986.3 | |
| ACCACGTGTTCTGGTTTCCAT | AAC CTCGCTGATTAGGCTCC | XM_011520852. | |
| 1 | |||
| CCTTCGCAAGCCCTCATTTC | AAATCCGAAGCCAGGTGTCC | NM_002701.5 | |
| ACAGCATGTCCTACTCGCAG | GAC TTGACCACCGAACCCAT | NM_ 003106.3 | |
| TCTGGTGCCTTTGAAGACCG | TACCCTTGCCAAGTTGCTGT | NM_001322195. | |
| 1 | |||
| GAAACAGTTGGGACCCCTGA | TACCGTGTGTCAAGCTGCTG | NM_139276.2 | |
| TGGTGGGGAACAAGTGTGAC | CGAGGTCTCGATGTAGGGGA | NM_005343.4 | |
| GCTCCTCCTCGCCCTCTT | CGCAGCTTCATGTCTGTGC | XM_024450641. | |
| 1 | |||
| TGGTGGGGAACAAGTGTGAC | CGAGGTCTCGATGTAGGGGA | BC_0011566.1 | |
| CAGCGGCCTCCGGTCTT | CCCAAGTTCTTGGAGTTAAGGGA | M12783.1 | |
| AAGTCTAGAGCCACCGTCCA | CAGTCTGGCTGCCAATCCA | NM_000546.5 | |
| CTTTAAGAAGGGACTTCCTCGCC | AAGTTCCGATCCCACCAGGA | NM_004322 | |
| CTGGGGATGTCCGTCAGAAC | CATTAGCGCATCACAGTCGC | BT006719.1 | |
| GTAACCCGTTGAACCCCATT | CCATCCAATCGGTAGTAGCG | NR_003286 |
PCNA: H. sapiens proliferating cell nuclear antigen, CCND1: H. sapiens cyclin D1, RRM2: H. sapiens ribonucleotide reductase M2, SIRT1: H. sapiens sirtuin 1, ALP: H. sapiens alkaline phosphatase, RUNX2: H. sapiens runt-related transcription factor 2, BGLAP: H. sapiens bone gamma-carboxyglutamate protein, LPL: H. sapiens lipoprotein lipase, PPAR: H. sapiens peroxisome proliferator activated receptor, PAX6: H. sapiens paired box 6, DCX: H. sapiens doublecortin, SOX1: H. sapiens SRY-box transcription factor 1, NANOG: H. sapiens Nanog homeobox; POU5F1/OCT4 : H. sapiens octamer-binding transcription factor 4; SOX2: H. sapiens SRY-box 2; JAK2:H. sapiens Janus kinase 2; STAT3:H. sapiens signal transducer and activator of transcription 3; Ras: H. sapiens HRas proto-oncogene, GTPase ; HER2: H. sapiens erb-b2 receptor tyrosine kinase 2; SRC: H. sapiens proto-oncogene tyrosine-protein kinase Src; C- Sis: H. sapiens c-sis protooncogene; p53: H. sapiens tumor protein; BAD: H. sapiens Bcl-2-associated death promoter; p21:H. sapiens cyclin-dependent kinase inhibitor 1A; 18S: H. sapiens ribosomal RNA.
Figure 2Comparisons of THSG-triggered proliferation in 2D and 3D culture systems. (A, B) Concentrations of THSG-treated human DPSCs in T25 flasks and spinner flasks. (C, D) Density of THSG-treated human DPSCs in T25 flasks and spinner flasks. (E, F) MTS assay. ∗, #, and $ indicate significantly different subsets obtained using the post hoc Bonferroni test if a significance of P < 0.05 was reached in one-way ANOVA.
The hDPSCs’ expansion rate in different culture system.
| Days | THSG ( μM) | |||||
|---|---|---|---|---|---|---|
| 0 | 0.1 | 10 | ||||
| T25 | Spinner | T25 | Spinner | T25 | Spinner | |
| 0 | 1 ± 0.01 | 1 ± 0.05 | 1 ± 0.01 | 1 ± 0.05 | 1 ± 0.01 | 1 ± 0.05 |
| 3 | 1.24 ± 0.04 | 1.18 ± 0.01 | 1.32 ± 0.04 | 1.45 ± 0.03 | 1.8 ± 0.04 | 2.13 ± 0.3 |
| 6 | 1.5 ± 0.03 | 1.4 ± 0.03 | 1.66 ± 0.11 | 2.00 ± 0.02∗ | 2.37 ± 0.12 | 3.41 ± 0.04∗ |
| 9 | 1.95 ± 0.05 | 1.85 ± 0.3 | 2.08 ± 0.08 | 3.05 ± 0.07∗ | 3.5 ± 0.3 | 4.14 ± 0.1∗ |
| 12 | 2.07 ± 0.12 | 2.05 ± 0.06 | 2.3 ± 0.3 | 4.00 ± 0.06∗∗ | 3.53 ± 0.31 | 5.85 ± 0.02∗∗ |
∗Significant differences from T25, p < 0.05; ∗∗Significant differences from T25, p < 0.01.
The hDPSCs’ expansion rate in different culture system.
| Days | THSG ( μM) | |||||
|---|---|---|---|---|---|---|
| 0 | 0.1 | 10 | ||||
| T25 | Spinner | T25 | Spinner | T25 | Spinner | |
| 0 | 1 ± 0.2 | 1 ± 0.09 | 1 ± 0.2 | 1 ± 0.09 | 1 ± 0.2 | 1 ± 0.09 |
| 3 | 1.24 ± 0.16 | 1.19 ± 0.02 | 1.31 ± 0.15 | 1.24 ± 0.09 | 1.8 ± 0.15 | 2.01 ± 0.06 |
| 6 | 1.5 ± 0.12 | 1.46 ± 0.05 | 1.66 ± 0.05 | 2.10 ± 0.04∗ | 2.37 ± 0.02 | 3.13 ± 0.07∗ |
| 9 | 1.95 ± 0.06 | 1.92 ± 0.05 | 2.08 ± 0.03 | 3.4 ± 0.04∗ | 3.25 ± 0.02 | 4.18 ± 0.03∗ |
| 12 | 2.07 ± 0.09 | 2.05 ± 0.07 | 2.3 ± 0.12 | 4.11 ± 0.07∗∗ | 3.38 ± 0.03 | 5.49 ± 0.1∗∗ |
∗Significant differences from T25, p < 0.05; ∗∗Significant differences from T25, p < 0.01.
Figure 3Effects of THSG on proliferation-related genes of DPSC in 2D and 3D culture systems. The expressions of PCNA, Cyclin D1, RRM2, and SIRT1 were measured through qPCR. (A) Cells were cultured in T25 flasks. (B) Cells were cultured in spinner flasks. Data are presented as means and standard deviations. ∗, #, and $ indicate significantly different subsets obtained using the post hoc Bonferroni test if a significance of P < 0.05 was reached in one-way ANOVA.
Figure 4Osteogenic effects of THSG on DPSCs in 2D and 3D cultures. The expressions of genes associated with osteogenesis (ALP, RUNX2, and BGLAP) were measured through qPCR. (A) Cells were cultured in T25 flasks. (B) Cells were cultured in spinner flasks. Data are presented as means and standard deviations. ∗, #, and $ indicate significantly different subsets obtained using the post hoc Bonferroni test if a significance of P < 0.05 was reached in one-way ANOVA.
Figure 5Adipogenic effects of THSG on DPSCs in 2D and 3D cultures. The mRNA expressions of LPL and PPAR were examined through qPCR. (A) Cells were cultured in T25 flasks. (B) Cells were cultured in spinner flasks. Data are presented as means and standard deviations. ∗, #, and $ indicate significantly different subsets obtained using the post hoc Bonferroni test if a significance of P < 0.05 was reached in one-way ANOVA.
Figure 6Neuronal differentiation effects of THSG on DPSCs in 2D and 3D cultures. The. expression levels of PAX6, DCX, and SOX1 were examined through qPCR. (A) Cells were cultured. In T25 flasks. (B) Cells were cultured in spinner flasks. Data are presented as means and standard deviations. ∗, #, and $ indicate significantly different subsets obtained using the post hoc Bonferroni test if a significance of P < 0.05 was reached in one-way ANOVA.
Figure 7Pluripotent effects of THSG on DPSCs in 2D and 3D cultures. The mRNA expressions of NANOG, POU5F1(OCT4), SOX2, and LIN28 were examined through qPCR. (A) Cells were cultured in T25 flasks. (B) Cells were cultured in spinner flasks. (C) The expression level of JAK2 and STAT3 of DPSCs treated with THSG in T25 and spinner flasks. Data are presented as means and standard deviations. ∗, #, and $ indicate significantly different subsets obtained using the post hoc Bonferroni test if a significance of P < 0.05 was reached in one-way ANOVA.
Figure.8Expression levels of oncogenes on THSG-treated DPSCs in 2D and 3D cultures. The expression levels of Ras, HER2, SRC, and C-Sis were examined through qPCR. (A) Cells were cultured in T25 flasks. (B) Cells were cultured in spinner flasks. Data are presented as means and standard deviations. ∗, #, and $ indicate significantly different subsets obtained using the post hoc Bonferroni test if a significance of P < 0.05 was reached in one-way ANOVA.
Figure 9Expression levels of apoptotic genes on THSG-treated DPSCs in 2D and 3D cultures. The expression levels of p53, BAD, and p21 in DPSCs were examined through qPCR. (A) Cells were cultured in T25 flasks. (B) Cells were cultured in spinner flasks. Data are presented as means and standard deviations. ∗, #, and $ indicate significantly different subsets obtained using the post hoc Bonferroni test if a significance of P < 0.05 was reached by one-way ANOVA.